This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human CD31 / PECAM-1 Protein, Fc Tag
catalog :
CD1-H5258
quantity :
200 ug, 1 mg
price :
340 USD, 1440 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
CD1-H5258
product name :
Human CD31 / PECAM-1 Protein, Fc Tag
quantity :
200 ug, 1 mg
price :
340 USD, 1440 USD
quantity & price :
$340/200ug,$1440/1mg
target :
CD31
host species :
Human
By Tag :
Fc Tag
Research :
For Research Use Only
Source :
Human CD31, Fc Tag (CD1-H5258) is expressed from human 293 cells (HEK293). It contains AA Gln 28 - Lys 601 (Accession # AAH22512.1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human CD31, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Cluster of Differentiation 31 (CD31) is also known as Platelet endothelial cell adhesion molecule (PECAM-1), is a 130-kDa transmembrane glycoprotein expressed by endothelial cells, platelets, macrophages and Kupffer cells, granulocytes, T / NK cells, lymphocytes, megakaryocytes, osteoclasts, neutrophils, certain tumors, and is the only known member of the CAM family on platelets. CD31 is found on the surface of platelets, monocytes, neutrophils, and some types of T-cells, and makes up a large portion of endothelial cell intercellular junctions. The encoded protein is a member of the immunoglobulin superfamily and is likely involved in leukocyte migration, angiogenesis, and integrin activation. CD31 plays a key role in removing aged neutrophils from the body. CD31 mediates the homotypic or heterotypic cell adhesion by binding to itself or the leukocyte integrin αvβ3, and thus plays a role in neutrophil recruitment in inflammatory responses, transendothelial migration of leukocytes, as well as in cardiovascular development. In addition, it has been shown that CD31 expression is up-regulated by LPS stimulation, and might function as a feedback negative regulator of LPS inflammatory response in macrophages.
References :
(1) Newman PJ, Newman DK., 2004, Arterioscler. Thromb. Vasc. Biol. 23 (6): 953–64.
(2) Kalinowska A, Losy J., 2007, Eur. J. Neurol. 13 (12): 1284–90.
(3) Almendro N, et al., 2007, J. Immunol. 157 (12): 5411–21.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments